Cargando…

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eusebi, Paolo, Romoli, Michele, Paoletti, Federico Paolini, Tambasco, Nicola, Calabresi, Paolo, Parnetti, Lucilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240081/ https://www.ncbi.nlm.nih.gov/pubmed/30480086 http://dx.doi.org/10.1038/s41531-018-0069-x

Ejemplares similares

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
por: Simoni, Simone, et al.
Publicado: (2022)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases
por: Costa, Cinzia, et al.
Publicado: (2022)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study
por: Tambasco, Nicola, et al.
Publicado: (2014)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
por: Tambasco, Nicola, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: König, Eva, et al.
Publicado: (2021)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease
por: Tirozzi, Alfonsina, et al.
Publicado: (2021)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
por: Herz, Damian M., et al.
Publicado: (2016)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
por: Li, Michael H., et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
por: Youn, Jinyoung, et al.
Publicado: (2022)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
por: Bispo, Ana Gabrielle, et al.
Publicado: (2023)

MAO-B Polymorphism Associated with Progression in a Chinese Parkinson's Disease Cohort but Not in the PPMI Cohort
por: Cui, Shi-Shuang, et al.
Publicado: (2022)

Extrastriatal (123)I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
por: Mihaescu, Alexander S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_554925b8soi1oe976gphm977fm